Home » Stocks » NK

NantKwest, Inc. (NK)

Stock Price: $9.70 USD 0.12 (1.25%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $9.76 +0.06 (0.62%) Dec 1, 7:36 PM

Stock Price Chart

Key Info

Market Cap 1.05B
Revenue (ttm) 99,000
Net Income (ttm) -75.89M
Shares Out 108.59M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $9.70
Previous Close $9.58
Change ($) 0.12
Change (%) 1.25%
Day's Open 9.68
Day's Range 9.47 - 10.67
Day's Volume 1,247,059
52-Week Range 1.41 - 15.36

More Stats

Market Cap 1.05B
Enterprise Value 980.91M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 108.59M
Float n/a
EPS (basic) -0.75
EPS (diluted) -0.75
FCF / Share -0.60
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.98M
Short Ratio 7.11
Short % of Float n/a
Beta 2.52
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 10,639.88
PB Ratio 5.51
Revenue 99,000
Operating Income -76.85M
Net Income -75.89M
Free Cash Flow -65.20M
Net Cash 72.44M
Net Cash / Share 0.67
Gross Margin 43.43%
Operating Margin -77,627.27%
Profit Margin -76,658.60%
FCF Margin -65,858.59%
ROA -28.19%
ROE -53.34%
ROIC -64.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(34.02% upside)
Current: $9.70
Target: 13.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-8.51%4.44%2.27%-81.36%-63.18%6.83%-
Gross Profit0.
Operating Income-67.81-98.39-99.12-125-239-5.58-2.27
Net Income-65.79-96.23-96.42-121-237-6.19-2.05
Shares Outstanding94.2179.1380.5881.9871.528.250.80
Earnings Per Share-0.70-1.22-1.20-1.47-3.31-0.75-2.57
Operating Cash Flow-61.36-63.38-48.78-38.59-25.31-5.42-0.67
Capital Expenditures-4.18-12.69-34.82-6.56-2.24-0.24-
Free Cash Flow-65.54-76.07-83.60-45.15-27.55-5.65-0.67
Cash & Equivalents51.6574.8712819929459.100.35
Total Debt10.895.951.742.03--1.76
Net Cash / Debt40.7768.9312619729459.10-1.41
Book Value12114621929335657.59-2.90
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name NantKwest, Inc.
Country United States
Employees 160
CEO Richard Adcock

Stock Information

Ticker Symbol NK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NK
IPO Date July 28, 2015


NantKwest, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.